Post-registration studies of the coronavirus vaccine, which was developed at the State Research Center for Virology and Biotechnology “Vector”, will begin in November-December. This was announced on Friday, October 2, by the Rospotrebnadzor press service.
“Post-registration studies of the EpiVacCorona vaccine with the participation of 5 thousand volunteers will begin after receiving the first batch of the drug, that is, in November-December 2020. The duration of these studies will be six months, “- noted in the TASS department.
On September 30, the head of Rospotrebnadzor, Anna Popova, spoke about the completion of clinical trials of the vaccine at the Vector Center. On the same day, the Federal Institute of Industrial Property granted Vektor patents for the drug.
On September 29, Russian Health Minister Mikhail Murashko said that the registration of the vaccine developed by Vector is expected within three weeks.
In early September, it was reported that all participants in the first phase of clinical trials of the Vector vaccine were discharged from the hospital and nine volunteers developed antibodies.
All relevant information on the situation with the coronavirus is available on the websites of stopcoronavirus.rf and accessvsem.rf, as well as by the hashtag #WeVotte. Coronavirus hotline: 8 (800) 2000-112.